Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D P Mikhailidis

Showing results (1-10 of 498) with videos related to

Pageof 50
Sort By:
Platelets|November 4, 2010
Computer programme reviewD P Mikhailidis
Current Medical Research and Opinion|July 24, 2001
The treatment of coronary heart disease: an update. Part 5: Selected comments and questionsD P Mikhailidis
Current Vascular Pharmacology|November 27, 2018
PrefaceD P Mikhailidis
Current Vascular Pharmacology|December 21, 2017
PrefaceD P Mikhailidis
British Medical Journal|February 25, 1978
Glucagon levels and vagotomyD P Mikhailidis
Current Pharmaceutical Design|November 15, 2011
There is more to predicting vascular disease than just established risk factorsManfredi Rizzo, D P Mikhailidis
International Journal of Cardiology|March 26, 2002
Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trialsE Rizos, D P Mikhailidis
Lancet (London, England)|March 20, 1982
Prostacyclin-stabilising-factor deficiency in thrombotic thrombocytopenic purpuraD P Mikhailidis, P Dandona
Current Medicinal Chemistry|September 5, 2015
Emerging Vascular Risk Factors in Women: Any Differences from Men?N Katsiki, D P Mikhailidis
Cardiovascular Research|October 31, 2001
Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?E Rizos, D P Mikhailidis
Pageof 50

Showing results (1-10 of 498) with videos related to

Sort By:
Pageof 50
Platelets|November 4, 2010
Computer programme reviewD P Mikhailidis
Current Medical Research and Opinion|July 24, 2001
The treatment of coronary heart disease: an update. Part 5: Selected comments and questionsD P Mikhailidis
Current Vascular Pharmacology|November 27, 2018
PrefaceD P Mikhailidis
Current Vascular Pharmacology|December 21, 2017
PrefaceD P Mikhailidis
British Medical Journal|February 25, 1978
Glucagon levels and vagotomyD P Mikhailidis
Current Pharmaceutical Design|November 15, 2011
There is more to predicting vascular disease than just established risk factorsManfredi Rizzo, D P Mikhailidis
International Journal of Cardiology|March 26, 2002
Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trialsE Rizos, D P Mikhailidis
Lancet (London, England)|March 20, 1982
Prostacyclin-stabilising-factor deficiency in thrombotic thrombocytopenic purpuraD P Mikhailidis, P Dandona
Current Medicinal Chemistry|September 5, 2015
Emerging Vascular Risk Factors in Women: Any Differences from Men?N Katsiki, D P Mikhailidis
Cardiovascular Research|October 31, 2001
Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?E Rizos, D P Mikhailidis
Pageof 50